Nature Podcast
Why we need to rethink how we talk about cancer
Feb 9, 2024
Cancer should be categorized based on molecular and genetic mechanisms instead of body parts. Changing how we name cancers can lead to tailored and efficient treatments. Naming based on organ of origin causes problems with clinical trials and training. A biology-based approach improves patient outcomes. Barriers like cost and perception can be overcome with AI and education. The speakers express gratitude and promote research opportunities.
14:53
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Cancer classification based on body parts can limit treatment options for metastatic cancer, advocating for a shift towards classifying cancers based on molecular or genetic causes to guide targeted therapies.
- A molecular-based cancer classification system offers advantages in drug development, hospital organization, and physician training, enabling the development of drugs that target specific molecular mechanisms and restructuring hospitals to focus on the biology of cancers.
Deep dives
Rethinking Cancer Classification
Cancer classification based on body parts can limit treatment options for metastatic cancer. Oncologists advocate for a shift towards classifying cancers based on molecular or genetic causes to guide targeted therapies. For instance, drugs that target specific molecular mechanisms have shown efficacy in certain types of cancer, but clinical trials organized by organ have caused delays in treatment for patients with specific biological features. Revising cancer classification based on molecular features would improve drug development, accelerate clinical trials, and facilitate patient understanding and engagement with treatment.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
